Novo Nordisk introduced a discounted multi‑month subscription program for its Wegovy obesity drugs on March 31, 2026. The program offers self‑pay patients the option to pre‑pay for 3, 6, or 12 months of Wegovy at a lower, predictable monthly rate. For the 12‑month plan, the injection and the newly launched pill are priced at $249 per month, translating to annual savings of up to $1,200 for the injection and $600 for the pill compared with the standard retail price.
The subscription model is available through a network of telehealth partners, including Weight Watchers, LifeMD, and Hims & Hers, with additional partners slated for future rollout. By shifting to a subscription framework, Novo Nordisk aims to reduce the out‑of‑pocket uncertainty that often deters self‑pay patients from initiating or continuing therapy.
The move is part of a broader strategy to improve patient adherence and expand access to Wegovy in a market where Eli Lilly’s tirzepatide (Zepbound) is gaining traction. Lower, predictable pricing is expected to attract patients who might otherwise forgo treatment, thereby helping Novo Nordisk maintain or grow its share of the GLP‑1 market.
Ed Cinca, senior vice president of Marketing & Patient Solutions, said the program is designed to "remove barriers, providing people who enroll a simple, affordable, and consistent way to start and stay on genuine, FDA‑approved treatment."
The subscription initiative signals a shift toward volume‑driven access and could influence future pricing and reimbursement discussions for Wegovy and other GLP‑1 products. By offering a cost‑predictable option, Novo Nordisk is positioning itself to respond to competitive pressures while supporting sustained patient use of its obesity therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.